welcomeThe King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions. We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.



The FIRST Registry

With the next generation of oral anticoagulants entering clinical practice, the FIRST registry will provide an important data tool to increase knowledge and improve the quality of care of patients with VTE. Read more...

Exemplar Centre Network website


The Exemplar Centre Network website has moved. After being hosted at the King's Thrombosis Centre website since its launch in 2007, the website will now be managed as part of the National VTE prevention Programme and can be accessed by clicking here.

Latest News

  • Anticoagulation news items. Week commencing18th May 2015
    Risk of Substantial Intraocular Bleeding With Novel Oral Anticoagulants: Systematic Review and Meta-analysis JAMA Oncology Analysis of 17 RCTs suggests no differences exist in the risk of substantial intraocular bleeding…
  • Anticoagulation news items. Week commencing11th May 2015
    Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation European Heart Journal RCT (n=248; VENTURE-AF) found that use of uninterrupted rivaroxaban was feasible and bleeding…
  • Anticoagulation news items. Week commencing 4th May 2015
    50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study The Lancet In this analysis (202,417 person-yrs), a roughly 4-times…